Guselkumab for children with active Crohn’s disease
Treatments studied
Part of Digestive system clinical trials.
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn’s disease (or fistulizing Crohn’s disease).
- Your Crohn’s symptoms are currently moderate to severe, based on a Crohn’s activity score (PCDAI 30 or higher).
- You had an endoscopy recently (within about 1 month before starting) showing active Crohn’s (SES-CD 6+ overall, or 4+ if disease is only in the ileum).
- You have tried treatments before and they did not work or stopped working, or you could not tolerate them (or you are dependent on steroids, or enteral nutrition alone did not help).
- You do NOT have complications that may need surgery soon, such as narrowing/strictures, short gut, or other surgery-likely problems.
- You do NOT have an abscess, and you have not had bowel surgery in the last 26 weeks or other abdominal surgery in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study is a long-term follow-up for children who have already finished an earlier study of guselkumab, a medicine for skin conditions like psoriasis. It looks at whether staying on the medicine continues to be safe and helpful over time.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.